Once damaged, it has limited ability to heal, leaving millions of people worldwide with permanent paralysis. However, a groundbreaking clinical trial in Japan has provided a glimmer of hope, showing ...

The significant drop in CNS Pharmaceuticals’ stock price reflects investor concerns over the commercial viability of Berubicin following these trial results. The company’s next steps will likely be ...